Anti-CD23 antibodies for the immunotherapeutic treatment of malignancies including B cell chronic lymphocytic leukaemia

摘要

The use of a CD23 antagonist is provided for the treatment of a neoplastic disorder. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particular the CD23 antagonists may be used to treat B cell chronic lymphocytic leukaemia (B-CLL). Fig. 13 graphically illustrates the anti-tumour activity of a CD23 antagonist in combination with RituxanT (rituximab) in a lymphoma/SCID mouse model.